Biotech Startups

An early-stage biotechnology company developing tissue-regenerative therapies based on the biotherapeutic calreticulin, with a first focus on a topical drug for diabetic foot ulcers. Its pipeline targets chronic and acute wound healing, corneal ulcers, soft tissue augmentation, and hair follicle regeneration.

1 investor

Tissue Form develops natural implants that preserve the body's extracellular matrix to restore lost tissue structure and enable integration. It works in the regenerative medicine field, targeting clinicians and partners across multiple tissue repair applications.

1 investor

Title21 provides software solutions for cellular therapy and biopharmaceutical manufacturing organizations, offering digital tools for patient coordination, manufacturing workflows, quality management, and regulatory compliance.

1 investor

Tivenix develops a machine-learning software platform that analyzes epigenetic signatures in blood plasma to provide non-invasive diagnosis and progression monitoring of Alzheimer's disease and other neurodegenerative diseases. The company targets clinical diagnostics and its platform integrates with data from other biomarkers.

1 investor

TiVentures is a seed-stage venture capital fund, owned by the Fondazione Centenario BancaStato, that invests in early-stage technology companies based in southern Switzerland (Ticino). It focuses on the life science, medical, high-tech, and IT sectors.

1 investor

TMD LAB develops shape memory polymer (SMP) materials and applies them across bio-medical, multi-dimensional printing, textile, and engineering fields. Its medical work includes SMP-based devices and implants such as lacrimal duct stents, biliary stents, punctal plugs, and vascular wrapping supports.

1 investor

Tocagen is a clinical-stage biotechnology company developing cancer-selective gene therapies designed to activate a patient's immune system against their own cancer. Its lead product candidate, Toca 511 & Toca FC, is being studied in a global Phase 3 trial for patients with brain cancer.

1 investor

Toleranzia AB was a biotech company whose business and operations were merged into Flerie AB in August 2025 and subsequently transferred to a new subsidiary later renamed Bonsai Biotherapeutics AB. The page functions as a merger notice rather than a product site.

1 investor

TOLREMO therapeutics develops small molecule inhibitors targeting transcriptional resistance mechanisms in cancer, with a lead clinical candidate TT125-802 designed for solid tumors and hematological malignancies as both monotherapy and combination treatment.

1 investor

Tomocube develops holotomography (HT), a label-free, non-invasive 3D microscopic imaging technology that combines with AI to visualize and quantify live cells, organoids, and tissue samples. Its systems and software serve life science researchers working in areas such as regenerative medicine, drug discovery, immunology, and cell therapy.

1 investor

Tomorrow Taste develops plant-based sweetener technology and beverages, creating protein-derived sweeteners for food and beverage manufacturers. The company serves brands seeking alternative sweetening solutions for consumer products.

1 investor

Topaz Therapeutics is developing a platform of next-generation oncology drugs.

1 investor

Rapid optical antimicrobial susceptibility testing platform

1 investor

Toralgen is a preclinical biopharmaceutical company developing oral drug delivery treatments for diabetes and autoimmune disorders using a poly-bile nanoparticle platform technology licensed from Yale University research.

1 investor

Torax Medical developed magnetic sphincter augmentation devices, including the LINX system for reflux and Fenix for fecal incontinence.

1 investor

Torpedo Therapeutics develops high-precision, closed-loop deep brain stimulation devices for treating neurological disorders including Parkinson's disease, essential tremor, dystonia, and drug-resistant epilepsy. The company uses micro- and nano-fabrication to create ultra-small electrode leads with machine learning-driven parameter adjustment to reduce side effects and improve treatment efficacy.

1 investor

Totus Medicines is a biopharmaceutical company developing small molecule drugs to address untreatable diseases by combining approaches in molecular design, structural biology, genetics, and cell biology. The company focuses on oncology and other therapeutic areas for patients with currently incurable conditions.

1 investor

Touchlight manufactures enzymatic DNA for genetic medicine applications, including mRNA and DNA vaccines, viral vector production, gene therapy, and genome editing. The company operates GMP-compliant manufacturing suites using cell-free DNA technology to produce pharmaceutical-grade plasmid DNA at commercial scale.

1 investor

Toxometris provides AI-powered in silico toxicity predictions for pharmaceutical compounds, combining mechanistic interpretability with predictive accuracy. The platform serves medicinal chemists and toxicologists for lead optimization, regulatory submission support, and compound library screening.

1 investor

ToxoTech is a biopharmaceutical company developing therapies for neurological disorders. It has announced a strategic collaboration with AAX Biotech to advance next-generation biotherapeutics.

1 investor

TPS is a global clinical research solutions company focused on study execution, connecting sponsors, sites, and patients to accelerate enrollment, improve retention, and assure data integrity. It positions itself as distinct from CROs and staffing agencies, offering services to convert sponsor spend into measurable trial outcomes.

1 investor

TQ Therapeutics develops cell and gene therapy technologies and processes to make challenging diseases curable. The company focuses on manufacturing and engineering advances in cell therapy for patient treatment.

1 investor

Traceless manufactures thermoplastic natural polymer-based materials that serve as plastic substitutes, operating the world's first industrial-scale production facility for these materials. The company serves manufacturers and brands seeking circular, biodegradable alternatives to conventional plastics.

1 investor

TRACER offers customized data quality services and analysis, emphasizing precision and speed to support faster decision-making for clients.

1 investor